Current Clinical Trials in Oncology

Boston Biomedical is developing the next generation of cancer therapeutics with investigational agents designed to inhibit cancer stemness pathways. The interactive graphic below lists current studies in advanced cancers, including those with metastatic disease in which the cancer has spread beyond the primary tumor site to lymph nodes and distant organs. BBI608 is also known as amcasertib (BBI-503) and as its generic name, napabucasin.

  • A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
  • A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
  • A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers
  • A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
  • A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
  • A Phase I/II Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors
  • A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies
  • A Study of Napabucasin (BBI608) in Combination With FOLFIRI With or Without Bevacizumab in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)
  • A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
  • A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
  • A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
  • A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
  • A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
  • A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
  • A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

References

For more information, please see the press release.

CanStem111P Trial

A Study of Napabucasin (BBI-608) Plus Weekly Nab-paclitaxel With Gemcitabine Versus Weekly Nab-paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Learn More

CanStem303C Trial

A Study of Napabucsin (BBI-608) in Combination with FOLFIRI in Adult Patients with Previously Treated Metastatic Colorectal Cancer (mCRC).

Learn More